TherapeuticsMD Stock Rating Reaffirmed by Noble Financial (TXMD)
In other TherapeuticsMD news, Director Cooper C. Collins bought 20,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $3.84 per share, for a total transaction of $76,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of other firms have also recently commented on TXMD. Analysts at JMP Securities initiated coverage on shares of TherapeuticsMD in a research note on Tuesday. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of TherapeuticsMD in a research note on Thursday, May 29th. They set a “buy” rating and a $7.00 price target on the stock. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $7.33.
Shares of TherapeuticsMD (NASDAQ:TXMD) traded up 0.40% on Wednesday, hitting $5.08. The stock had a trading volume of 4,746,077 shares. TherapeuticsMD has a 52 week low of $2.03 and a 52 week high of $9.01. The stock has a 50-day moving average of $4.05 and a 200-day moving average of $5.32. The company’s market cap is $738.8 million.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Tuesday, May 6th. The company reported ($0.06) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.06). The company had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.08 million. During the same quarter last year, the company posted ($0.06) earnings per share. On average, analysts predict that TherapeuticsMD will post $-0.28 earnings per share for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.